This is an old revision of the document!

Norrie Disease

Main Features

  • X-linked recessive disorder caused by mutations in the NDP gene (Xp11.3)
    • encodes norrin, a secreted Wnt-pathway ligand for frizzled-4
    • Essential for retinal and inner-ear vascular development
  • Retinal vascular developmental defects lead to
    • Avascular peripheral retina
    • Retinal gliosis and vitreous
    • Retinal detachment
      • Congenital bilateral blindness
  • Progressive sensorineural hearing loss occurs in ~30%, usually later onset (childhood into adulthood).
  • Neurodevelopmental
    • Developmental/motor delay (~30–50%), mild-to-moderate intellectual disability, behavioral problems/psychosis, autism features, and seizures.
    • Larger deletions (complete norrin loss) → more severe multisystem disease.

Eye Findings

  • Retrolental mass (“pseudoglioma”) — grayish-yellow mass of immature retinal cells resembling retinoblastoma, present at or shortly after birth.
  • Leukocoria — hallmark sign; with retinal dysplasia and partial/complete retinal detachment.
  • Progressive anterior/globe changes — cataract, corneal opacification, iris atrophy, synechiae, secondary glaucoma/buphthalmos, and eventual phthisis bulbi, typically within the first decade.
  • Microphthalmia and nystagmus are common.

Other Findings

  • Auditory: progressive sensorineural hearing loss in ~30%, requiring surveillance and eventual hearing aids/cochlear implantation.*[1][2][5][6]
  • Neurodevelopmental/psychiatric: developmental delay, intellectual disability, psychosis/behavioral problems, autism features, seizures.*[1][2][4]
  • Allelic conditions (NDP-related retinopathies): familial exudative vitreoretinopathy (FEVR), [Coats disease](https://www.openevidence.com/rare-disease/coats-disease), persistent fetal vasculature (PHPV), and retinopathy of prematurity.

Etiology

  • Gene/inheritance: pathogenic variants in NDP, inherited X-linked recessive; affected males hemizygous, carrier females typically unaffected. >115 mutations reported (missense, splice, intragenic/large deletions), with genotype–phenotype correlation (deletions → severe).
  • Mechanism: loss of norrin disrupts Wnt/frizzled-4 signaling required for retinal and cochlear vascular development and retinal cell specification.
  • Differential/phenocopies: truncating CTNNB1 mutations can cause a Norrie-like phenotype, with overlap with KIF11; ~30% of clinically diagnosed families have no identifiable NDP variant.
  • Genetic testing: Sanger sequencing for point mutations/small indels; deletion/duplication analysis (MLPA/dosage) for large deletions; NGS/whole-exome sequencing for ambiguous cases or to capture CTNNB1/KIF11. Once the familial variant is known, carrier, prenatal (amniocentesis/CVS), and preimplantation testing are available; third-trimester ultrasound may suggest the diagnosis. * Treatment (supportive, multidisciplinary; no approved disease-modifying therapy): * **Ocular — individualized pediatric vitreoretinal care; most infants have complete detachment at birth limiting surgery to preserving light perception/globe. In eyes without complete detachment, prophylactic laser photocoagulation at/shortly after birth has preserved useful vision. Vitrectomy (± lensectomy) in selected infants; manage secondary glaucoma; enucleation occasionally for a painful blind eye. * Auditory — audiologic monitoring, hearing aids, cochlear implantation. * Neurodevelopmental — developmental, behavioral, educational support; seizure and psychiatric management. * Emerging — systemic **AAV9-mediated //NDP gene therapy** rescued retinal and cochlear pathology in a Norrie mouse model (preclinical).

Resources